首页> 外文期刊>Current Microbiology: An International Journal >Optimized expression of Helicobacter pylori ureB gene in the Lactococcus lactis nisin-controlled gene expression (NICE) system and experimental study of its immunoreactivity
【24h】

Optimized expression of Helicobacter pylori ureB gene in the Lactococcus lactis nisin-controlled gene expression (NICE) system and experimental study of its immunoreactivity

机译:幽门螺杆菌ureB基因在乳酸乳球菌乳链菌肽控制基因表达(NICE)系统中的优化表达及其免疫反应性的实验研究

获取原文
获取原文并翻译 | 示例
           

摘要

In the development of an oral vaccine against Helicobacter pylori, H. pylori urease subunit B (UreB) was expressed in a food-grade delivery vehicle, Lactococcus lactis NZ3900. The ureB gene (Genbank accession no. FJ436980) was amplified by polymerase chain reaction (PCR) from MEL-Hp27. The PCR-amplified ureB gene was cloned in the E. coli-L. lactis shuttle vector pNZ8110 and transformed into E. coli MC1061. After the transformant had been identified, the recombinant plasmid was purified and electrotransformed into L. lactis NZ3900. The conditions of UreB expression in the L. lactis transformant were optimized by orthogonal experiment. The maltose binding protein (MBP)-UreB fusion protein expressed by TB(1)/pMAL-c2X-ureB was used to cultivate mice polyclonal anti-UreB serum after purification by the amylose prepacked column. The Western blot method was adopted to confirm whether the UreB expressed by L. lactis transformant had immunoreactivity. The optimized conditions for UreB expression were as follows. Nisin 40 ng/ml was added to the medium when the recombinant grew to OD(600) approximately 0.30-0.40 and the induction time lasted 5 h. As a result, the maximum yield of UreB was 27.26 microg/mL of medium, and the maximum percentage of UreB in cell extracts of the L. lactis transformant reached its peak at 20.19%. Western blot analysis showed that the UreB protein expressed by L. lactis transformant had favorable immunoreactivity. All these results make an appealing case for construction of the food-grade vaccine for H. pylori.
机译:在开发针对幽门螺杆菌的口服疫苗时,幽门螺杆菌脲酶B亚单位(UreB)在食品级递送载体乳酸乳球菌NZ3900中表达。通过聚合酶链反应(PCR)从MEL-Hp27扩增ureB基因(Genbank登录号FJ436980)。将PCR扩增的ureB基因克隆到大肠杆菌L中。乳酸穿梭载体pNZ8110,并转化到大肠杆菌MC1061中。鉴定出转化体后,将重组质粒纯化并电转化为乳酸乳球菌NZ3900。通过正交实验优化了乳酸乳球菌转化子中UreB表达的条件。 TB(1)/ pMAL-c2X-ureB表达的麦芽糖结合蛋白(MBP)-UreB融合蛋白经直链淀粉预填充柱纯化后,用于培养小鼠多克隆抗UreB血清。采用蛋白质印迹法确认乳酸乳杆菌转化子表达的UreB是否具有免疫反应性。 UreB表达的优化条件如下。当重组体生长到大约0.30-0.40的OD(600)并且诱导时间持续5小时时,将Nisin 40ng / ml添加到培养基中。结果,UreB的最大产量为27.26μg/ mL培养基,并且乳酸乳球菌转化体的细胞提取物中UreB的最大百分比达到其峰值,为20.19%。 Western印迹分析表明,乳酸乳杆菌转化子表达的UreB蛋白具有良好的免疫反应性。所有这些结果为构建幽门螺杆菌食品级疫苗提供了诱人的理由。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号